Biotech Values

[pcrutch]

I support them writing an article about Momenta, but all these financial journalists are just so mediocre. As someone pointed out, how did they fail to mention that Copaxone could be approved this year? Also, they seem to have forgotten to mention that MNTA is suing TEVA, in regards to Lovenox development. The lack of any detail is astounding.

I expected much higher quality out of Barron's. This was written at about the level the Motley Fool or the Street.com puts out. In terms of bond status, I give them a BBB+. Motley and the Street are CCC and below; straight up junk.